SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its f...


    
    
    
          
		  
          
            
            
            ,  /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 7, 2024.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts:
For Investors:                                                                                             Vivian Wu of Nektar Therapeutics(628) 895-0661
For Media:Madelin HawtinLifeSci Communications603-714-2638mhawtin@lifescicomms.com
SOURCE Nektar Therapeutics





        
            WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

        
        
            
        
            
        
            
        
            
        
            
        
            
        
            
        
            
                
                    
                        
                        
                        
                            440k+
Newsrooms &
Influencers
                        
                    
                
                    
                        
                        
                        
                            9k+
Digital Media
Outlets
                        
                    
                
                    
                        
                        
                        
                            270k+
Journalists
Opted In
                        
                    
                
            
        
        
    
          
        

  

NKTR

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Nektar Therapeutics will announce Q3 2024 results on November 7.
CEO Howard Robin will host a conference call at 5 PM ET.
Focused on immunological treatments with key clinical trials ongoing.
Lead candidate REZPEG is in Phase 2b trials for specific diseases.

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Information

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Earnings

Related News